Conditioning with α-emitter based radioimmunotherapy in canine allogeneic hematopoietic cell transplantation

References

• McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97:3390 - 400; http://dx.doi.org/10.1182/blood.V97.11.3390; PMID: 11369628
   PubMed Web of Science ®Google Scholar
• Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101:1620 - 9; http://dx.doi.org/10.1182/blood-2002-05-1340; PMID: 12393457
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Matthews DC, Eary JF, Badger CC, Kellogg M, Press OW, et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 1992; 54:829 - 33; http://dx.doi.org/10.1097/00007890-199211000-00012; PMID: 1440849
   PubMed Web of Science ®Google Scholar
• Bunjes D, Buchmann I, Duncker C, Seitz U, Kotzerke J, Wiesneth M, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood 2001; 98:565 - 72; http://dx.doi.org/10.1182/blood.V98.3.565; PMID: 11468151
   PubMed Web of Science ®Google Scholar
• Pagel JM, Gooley TA, Rajendran J, Fisher DR, Wilson WA, Sandmaier BM, et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 2009; 114:5444 - 53; http://dx.doi.org/10.1182/blood-2009-03-213298; PMID: 19786617
   PubMed Web of Science ®Google Scholar
• Schulz AS, Glatting G, Hoenig M, Schuetz C, Gatz SA, Grewendorf S, et al. Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases. Blood 2011; 117:4642 - 50; http://dx.doi.org/10.1182/blood-2010-06-284349; PMID: 21325170
   PubMed Web of Science ®Google Scholar
• Wilbur DS. Potential use of alpha emitting radionuclides in the treatment of cancer. Antibody, Immunoconjugates, and Radiopharmaceuticals 1991; 4:85 - 97
   Google Scholar
• Raju MR, Eisen Y, Carpenter S, Inkret WC. Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus. Radiat Res 1991; 128:204 - 9; http://dx.doi.org/10.2307/3578139; PMID: 1947017
   PubMed Web of Science ®Google Scholar
• Dadachova E. Cancer therapy with alpha-emitters labeled peptides. Semin Nucl Med 2010; 40:204 - 8; http://dx.doi.org/10.1053/j.semnuclmed.2010.01.002; PMID: 20350629
   PubMed Web of Science ®Google Scholar
• Kennel SJ, Stabin M, Roeske JC, Foote LJ, Lankford PK, Terzaghi-Howe M, et al. Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells. Radiat Res 1999; 151:244 - 56; http://dx.doi.org/10.2307/3579935; PMID: 10073661
   PubMed Web of Science ®Google Scholar
• Omary MB, Trowbridge IS, Battifora HA. Human homologue of murine T200 glycoprotein. J Exp Med 1980; 152:842 - 52; http://dx.doi.org/10.1084/jem.152.4.842; PMID: 6968338
   PubMed Web of Science ®Google Scholar
• Andres TL, Kadin ME. Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia. Am J Clin Pathol 1983; 79:546 - 52; PMID: 6188365
   PubMed Web of Science ®Google Scholar
• Nakamura H, Gress RE. Graft rejection by cytolytic T cells. Specificity of the effector mechanism in the rejection of allogeneic marrow. Transplantation 1990; 49:453 - 8; http://dx.doi.org/10.1097/00007890-199002000-00042; PMID: 2305471
   PubMed Web of Science ®Google Scholar
• Kikly K, Dennert G. Evidence for a role for T cell receptors (TCR) in the effector phase of acute bone marrow graft rejection. TCR V beta 5 transgenic mice lack effector cells able to cause graft rejection. J Immunol 1992; 149:3489 - 94; PMID: 1431119
   PubMed Web of Science ®Google Scholar
• Raff RF, Sandmaier BM, Graham T, Loughran TP Jr., Pettinger M, Storb R. “Resistance” to DLA-nonidentical canine unrelated marrow grafts is unrestricted by the major histocompatibility complex. Exp Hematol 1994; 22:893 - 7; PMID: 8062888
   PubMed Web of Science ®Google Scholar
• Sandmaier BM, Bethge WA, Wilbur DS, Hamlin DK, Santos EB, Brechbiel MW, et al. Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood 2002; 100:318 - 26; http://dx.doi.org/10.1182/blood-2001-12-0322; PMID: 12070043
   PubMed Web of Science ®Google Scholar
• Bethge WA, Wilbur DS, Storb R, Hamlin DK, Santos EB, Brechbiel MW, et al. Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: a dose deescalation study. Transplantation 2004; 78:352 - 9; http://dx.doi.org/10.1097/01.TP.0000128853.62545.B2; PMID: 15316362
   PubMed Web of Science ®Google Scholar
• Nakamae H, Wilbur DS, Hamlin DK, Thakar MS, Santos EB, Fisher DR, et al. Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the α-emitting radionuclides bismuth-213 or astatine-211. Cancer Res 2009; 69:2408 - 15; http://dx.doi.org/10.1158/0008-5472.CAN-08-4363; PMID: 19244101
   PubMed Web of Science ®Google Scholar
• Wilbur DS, Chyan M-K, Nakamae H, Chen Y, Hamlin DK, Santos EB, et al. Reagents for astatination of Biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines. Bioconjug Chem 2012; 23:409 - 20; http://dx.doi.org/10.1021/bc200401b; PMID: 22296587
   PubMed Web of Science ®Google Scholar
• Chen Y, Kornblit B, Hamlin DK, Sale GE, Santos EB, Wilbur DS, et al. Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. Blood 2012; 119:1130 - 8; http://dx.doi.org/10.1182/blood-2011-09-380436; PMID: 22134165
   PubMed Web of Science ®Google Scholar
• Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem H-P, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89:3048 - 54; PMID: 9108426
   PubMed Web of Science ®Google Scholar
• Chen Y, Fukuda T, Thakar MS, Kornblit BT, Storer BE, Santos EB, et al. Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complex-haplo-identical non-myeloablative hematopoietic cell transplantation. Cytotherapy 2011; 13:1269 - 80; http://dx.doi.org/10.3109/14653249.2011.586997; PMID: 21846291
   PubMed Web of Science ®Google Scholar
• Nakamae H, Kerbauy FR, Wilbur DS, Bethge W, Hamlin DK, Santos EB, et al. Pilot study of a (213)bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation. Transplantation 2010; 89:1336 - 40; http://dx.doi.org/10.1097/TP.0b013e3181d98c3d; PMID: 20351629
   PubMed Web of Science ®Google Scholar
• Kuhr CS, Allen MD, Junghanss C, Zaucha JM, Marsh CL, Yunusov M, et al. Tolerance to vascularized kidney grafts in canine mixed hematopoietic chimeras. Transplantation 2002; 73:1487 - 92; http://dx.doi.org/10.1097/00007890-200205150-00020; PMID: 12023629
   PubMed Web of Science ®Google Scholar
• Mathes DW, Hwang B, Graves SS, Edwards J, Chang J, Storer BE, et al. Tolerance to vascularized composite allografts in canine mixed hematopoietic chimeras. Transplantation 2011; 92:1301 - 8; http://dx.doi.org/10.1097/TP.0b013e318237d6d4; PMID: 22082819
   PubMed Web of Science ®Google Scholar
• Touchefeu Y, Franken P, Harrington KJ. Radiovirotherapy: Principles and prospects in oncology. Current Pharmceutical Design 2012; 18:3313 - 20; PMID: 22397732
   PubMed Web of Science ®Google Scholar
• Petrich T, Helmeke HJ, Meyer GJ, Knapp WH, Pötter E. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter. Eur J Nucl Med Mol Imaging 2002; 29:842 - 54; http://dx.doi.org/10.1007/s00259-002-0784-7; PMID: 12111124
   PubMed Web of Science ®Google Scholar